Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients

Thomas J. Polascik, Michael J. Manyak, Michael K. Haseman, Robin T. Gurganus, Barbara Rogers, Robert T. Maguire, Alan Wayne Partin

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The pretherapy prediction of occult lymph node involvement and the avoidance of otherwise futile and potentially morbid definitive local therapy is paramount in men with newly diagnosed prostate carcinoma. To identify patients with prostate carcinoma who likely have lymph node involvement and would benefit from staging lymphadenectomy prior to definitive local therapy, the authors compared the ability of several predictive staging algorithms and a radiolabeled monoclonal antibody scan to predict lymphatic metastases prior to treatment. METHODS. Between August 1991 and June 1994, 198 men with clinical T2 or T3 classified (TNM) prostate carcinoma (bone scan negative) who were at high risk of lymph node involvement underwent a 111In-capromab pendetide scan prior to staging lymphadenectomy. Several predictive models based on preoperative prostate specific antigen level, biopsy Gleason score, and clinical stage were selected to predict those men having a ≥20% probability of lymph node involvement. The ability to predict pathologic stage using several clinical algorithms and the monoclonal antibody scan was compared with pathologic examination of the lymph nodes. RESULTS. Overall, 39% of the pelvic lymph node specimens were positive for metastatic disease by pathologic analysis. Published algorithms predicting lymph node metastases had a positive predictive value (PPV) ranging from 40.5% to 46.6% and an area under the receiver operating characteristic curve (AUC) ranging from 0.52 to 0.61. The monoclonal antibody scan had a PPV of 66.7% and an AUC of 0.71. The differences between the PPV and the AUC for the individual clinical algorithms when compared with immunoscintigraphy were statistically significant. Combining the radiolabeled monoclonal antibody scan with clinical predictive models, a PPV of up to 72.1% could be obtained. CONCLUSIONS. These data suggest that the PPVs for the clinical predictive algorithms are similar and that the PPV of the radiolabeled monoclonal antibody scan alone or in combination with the algorithms has additional value in predicting lymph node involvement in prostate carcinoma patients at high risk of regional disease spread. These algorithms and the 111In- capromab pendetide scan may be used for the appropriate selection of candidates for definitive local therapy in men with clinically localized prostate carcinoma and significant risk of lymph node involvement.

Original languageEnglish (US)
Pages (from-to)1586-1592
Number of pages7
JournalCancer
Volume85
Issue number7
DOIs
StatePublished - Apr 1 1999

Fingerprint

Prostate
Lymph Nodes
Carcinoma
Monoclonal Antibodies
Area Under Curve
Lymph Node Excision
Lymphatic Metastasis
Capromab Pendetide
Neoplasm Grading
Therapeutics
Prostate-Specific Antigen
ROC Curve
Neoplasm Metastasis
Biopsy
Bone and Bones

Keywords

  • Indium-capromab pendetide
  • Immunoscintigraphy
  • Lymph node involvement
  • Prostate carcinoma
  • Staging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. / Polascik, Thomas J.; Manyak, Michael J.; Haseman, Michael K.; Gurganus, Robin T.; Rogers, Barbara; Maguire, Robert T.; Partin, Alan Wayne.

In: Cancer, Vol. 85, No. 7, 01.04.1999, p. 1586-1592.

Research output: Contribution to journalArticle

Polascik, Thomas J. ; Manyak, Michael J. ; Haseman, Michael K. ; Gurganus, Robin T. ; Rogers, Barbara ; Maguire, Robert T. ; Partin, Alan Wayne. / Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. In: Cancer. 1999 ; Vol. 85, No. 7. pp. 1586-1592.
@article{b596e7610c1347ffa103077d92b010b6,
title = "Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients",
abstract = "BACKGROUND. The pretherapy prediction of occult lymph node involvement and the avoidance of otherwise futile and potentially morbid definitive local therapy is paramount in men with newly diagnosed prostate carcinoma. To identify patients with prostate carcinoma who likely have lymph node involvement and would benefit from staging lymphadenectomy prior to definitive local therapy, the authors compared the ability of several predictive staging algorithms and a radiolabeled monoclonal antibody scan to predict lymphatic metastases prior to treatment. METHODS. Between August 1991 and June 1994, 198 men with clinical T2 or T3 classified (TNM) prostate carcinoma (bone scan negative) who were at high risk of lymph node involvement underwent a 111In-capromab pendetide scan prior to staging lymphadenectomy. Several predictive models based on preoperative prostate specific antigen level, biopsy Gleason score, and clinical stage were selected to predict those men having a ≥20{\%} probability of lymph node involvement. The ability to predict pathologic stage using several clinical algorithms and the monoclonal antibody scan was compared with pathologic examination of the lymph nodes. RESULTS. Overall, 39{\%} of the pelvic lymph node specimens were positive for metastatic disease by pathologic analysis. Published algorithms predicting lymph node metastases had a positive predictive value (PPV) ranging from 40.5{\%} to 46.6{\%} and an area under the receiver operating characteristic curve (AUC) ranging from 0.52 to 0.61. The monoclonal antibody scan had a PPV of 66.7{\%} and an AUC of 0.71. The differences between the PPV and the AUC for the individual clinical algorithms when compared with immunoscintigraphy were statistically significant. Combining the radiolabeled monoclonal antibody scan with clinical predictive models, a PPV of up to 72.1{\%} could be obtained. CONCLUSIONS. These data suggest that the PPVs for the clinical predictive algorithms are similar and that the PPV of the radiolabeled monoclonal antibody scan alone or in combination with the algorithms has additional value in predicting lymph node involvement in prostate carcinoma patients at high risk of regional disease spread. These algorithms and the 111In- capromab pendetide scan may be used for the appropriate selection of candidates for definitive local therapy in men with clinically localized prostate carcinoma and significant risk of lymph node involvement.",
keywords = "Indium-capromab pendetide, Immunoscintigraphy, Lymph node involvement, Prostate carcinoma, Staging",
author = "Polascik, {Thomas J.} and Manyak, {Michael J.} and Haseman, {Michael K.} and Gurganus, {Robin T.} and Barbara Rogers and Maguire, {Robert T.} and Partin, {Alan Wayne}",
year = "1999",
month = "4",
day = "1",
doi = "10.1002/(SICI)1097-0142(19990401)85:7<1586::AID-CNCR21>3.0.CO;2-F",
language = "English (US)",
volume = "85",
pages = "1586--1592",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients

AU - Polascik, Thomas J.

AU - Manyak, Michael J.

AU - Haseman, Michael K.

AU - Gurganus, Robin T.

AU - Rogers, Barbara

AU - Maguire, Robert T.

AU - Partin, Alan Wayne

PY - 1999/4/1

Y1 - 1999/4/1

N2 - BACKGROUND. The pretherapy prediction of occult lymph node involvement and the avoidance of otherwise futile and potentially morbid definitive local therapy is paramount in men with newly diagnosed prostate carcinoma. To identify patients with prostate carcinoma who likely have lymph node involvement and would benefit from staging lymphadenectomy prior to definitive local therapy, the authors compared the ability of several predictive staging algorithms and a radiolabeled monoclonal antibody scan to predict lymphatic metastases prior to treatment. METHODS. Between August 1991 and June 1994, 198 men with clinical T2 or T3 classified (TNM) prostate carcinoma (bone scan negative) who were at high risk of lymph node involvement underwent a 111In-capromab pendetide scan prior to staging lymphadenectomy. Several predictive models based on preoperative prostate specific antigen level, biopsy Gleason score, and clinical stage were selected to predict those men having a ≥20% probability of lymph node involvement. The ability to predict pathologic stage using several clinical algorithms and the monoclonal antibody scan was compared with pathologic examination of the lymph nodes. RESULTS. Overall, 39% of the pelvic lymph node specimens were positive for metastatic disease by pathologic analysis. Published algorithms predicting lymph node metastases had a positive predictive value (PPV) ranging from 40.5% to 46.6% and an area under the receiver operating characteristic curve (AUC) ranging from 0.52 to 0.61. The monoclonal antibody scan had a PPV of 66.7% and an AUC of 0.71. The differences between the PPV and the AUC for the individual clinical algorithms when compared with immunoscintigraphy were statistically significant. Combining the radiolabeled monoclonal antibody scan with clinical predictive models, a PPV of up to 72.1% could be obtained. CONCLUSIONS. These data suggest that the PPVs for the clinical predictive algorithms are similar and that the PPV of the radiolabeled monoclonal antibody scan alone or in combination with the algorithms has additional value in predicting lymph node involvement in prostate carcinoma patients at high risk of regional disease spread. These algorithms and the 111In- capromab pendetide scan may be used for the appropriate selection of candidates for definitive local therapy in men with clinically localized prostate carcinoma and significant risk of lymph node involvement.

AB - BACKGROUND. The pretherapy prediction of occult lymph node involvement and the avoidance of otherwise futile and potentially morbid definitive local therapy is paramount in men with newly diagnosed prostate carcinoma. To identify patients with prostate carcinoma who likely have lymph node involvement and would benefit from staging lymphadenectomy prior to definitive local therapy, the authors compared the ability of several predictive staging algorithms and a radiolabeled monoclonal antibody scan to predict lymphatic metastases prior to treatment. METHODS. Between August 1991 and June 1994, 198 men with clinical T2 or T3 classified (TNM) prostate carcinoma (bone scan negative) who were at high risk of lymph node involvement underwent a 111In-capromab pendetide scan prior to staging lymphadenectomy. Several predictive models based on preoperative prostate specific antigen level, biopsy Gleason score, and clinical stage were selected to predict those men having a ≥20% probability of lymph node involvement. The ability to predict pathologic stage using several clinical algorithms and the monoclonal antibody scan was compared with pathologic examination of the lymph nodes. RESULTS. Overall, 39% of the pelvic lymph node specimens were positive for metastatic disease by pathologic analysis. Published algorithms predicting lymph node metastases had a positive predictive value (PPV) ranging from 40.5% to 46.6% and an area under the receiver operating characteristic curve (AUC) ranging from 0.52 to 0.61. The monoclonal antibody scan had a PPV of 66.7% and an AUC of 0.71. The differences between the PPV and the AUC for the individual clinical algorithms when compared with immunoscintigraphy were statistically significant. Combining the radiolabeled monoclonal antibody scan with clinical predictive models, a PPV of up to 72.1% could be obtained. CONCLUSIONS. These data suggest that the PPVs for the clinical predictive algorithms are similar and that the PPV of the radiolabeled monoclonal antibody scan alone or in combination with the algorithms has additional value in predicting lymph node involvement in prostate carcinoma patients at high risk of regional disease spread. These algorithms and the 111In- capromab pendetide scan may be used for the appropriate selection of candidates for definitive local therapy in men with clinically localized prostate carcinoma and significant risk of lymph node involvement.

KW - Indium-capromab pendetide

KW - Immunoscintigraphy

KW - Lymph node involvement

KW - Prostate carcinoma

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=0033120306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033120306&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990401)85:7<1586::AID-CNCR21>3.0.CO;2-F

DO - 10.1002/(SICI)1097-0142(19990401)85:7<1586::AID-CNCR21>3.0.CO;2-F

M3 - Article

C2 - 10193950

AN - SCOPUS:0033120306

VL - 85

SP - 1586

EP - 1592

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -